Serotonin-3 Receptor Antagonist Drug Class List

Drugs in Drug Class: Serotonin-3 Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	SUSTOL	granisetron	INJECTABLE;SUBCUTANEOUS	022445-001	Aug 9, 2016		RX	Yes	Yes
Cumberland	SANCUSO	granisetron	FILM, EXTENDED RELEASE;TRANSDERMAL	022198-001	Sep 12, 2008		RX	Yes	Yes
Avyxa Holdings	POSFREA	palonosetron hydrochloride	SOLUTION;INTRAVENOUS	203050-001	Mar 1, 2016		DISCN	Yes	No
Avyxa Holdings	POSFREA	palonosetron hydrochloride	SOLUTION;INTRAVENOUS	203050-002	Mar 1, 2016		RX	Yes	Yes
Teva Pharms Usa	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	090713-002	Mar 23, 2018		DISCN	No	No

Market Dynamics and Patent Landscape for Serotonin-3 Receptor Antagonist Drugs

Last updated: July 2, 2026

Executive summary. Serotonin-3 (5-HT3) receptor antagonists remain a mature, high-value antiemetic class anchored by a small set of reference brands, led by ondansetron products and granisetron products in the US market. Patent coverage is concentrated in (1) composition-of-matter and (2) second-generation lifecycle patents covering salts, crystalline forms, fixed-dose combinations, and manufacturing and dose-form innovations (notably injectables and orally disintegrating or modified-release formats). As primary patents expire across major actives, the market shifts toward generic and biosimilar-style small-molecule competition via ANDA filings and periodic settlement-driven entry windows. Across the class, the strongest remaining IP tends to cluster around granisetron and select ondansetron product formats where crystalline/solid-state or device-adjacent formulations are protected, while bulk ondansetron generics face broad commercial pressure and fewer enforceable remaining barriers.

---

What 5-HT3 receptor antagonists dominate the market and how do they compete on patent life?

Featured snippet answer: The 5-HT3 antagonist market is led by ondansetron and granisetron brands. Patent leverage is highest in products with live protections on specific salt/forms and formulation dose forms rather than the core pharmacophore.

Core market anchors and typical use cases

5-HT3 receptor antagonists are used for:

• Chemotherapy-induced nausea and vomiting (CINV)
• Radiation-induced nausea and vomiting (RINV)
• Post-operative nausea and vomiting (PONV)

Competitive structure: “few actives, many products”

The class is characterized by:

• A small active ingredient set (ondansetron, granisetron, palonosetron, dolasetron historically)
• Large product proliferation across:
  • IV/IM solutions
  • Oral tablets
  • Orally disintegrating tablets (ODT)
  • Extended-release or branded convenience formats

Implication for patent strategy. Where base molecules are old, the business question becomes whether remaining patents still cover a commercially relevant product format in a key delivery system.

---

What patents protect ondansetron and which exclusivities drive market access?

Featured snippet answer: Ondansetron’s core patent estate has largely aged out in most major markets; remaining leverage typically sits in specific product formats (salts, solid state forms, and formulation/process IP) tied to particular ANDA-relevant SKUs.

Composition-of-matter vs. formulation patents: how the landscape typically breaks

For ondansetron, patent protection historically spanned:

• Salts/polymorphs and crystalline forms
• Stable aqueous compositions for injectable products
• Manufacturing processes controlling impurities and stability
• Fast-dissolve or ODT technologies

Where a brand still commands pricing, that usually reflects:

• SKU-specific patent coverage that blocks certain generic formulations
• Or exclusivity tied to new dosage forms approved after the reference molecule’s era

Regulatory exclusivity interactions (typical mechanics)

• 3-year exclusivity can attach to new clinical studies.
• 5-year exclusivity attaches to new chemical entities (rare for ondansetron).
• For lifecycle changes, the key is whether the change is eligible for exclusivity and whether any granted patents remain listed for the relevant NDA/BLA SKU.

---

What patents protect granisetron and how strong is the patent estate?

Featured snippet answer: Granisetron typically has more visible remaining lifecycle-style protection in commercially specific forms such as injectables and selected oral presentations. The strongest estate tends to involve solid-state and formulation-specific patents rather than broad new-entity exclusivity.

Patent strength drivers in granisetron product families

Business-relevant IP drivers include:

• Crystalline form coverage and control of polymorphic behavior during scale-up
• Stability and impurity profile patents for injection or stored solutions
• Formulation systems that are difficult to replicate without infringing solid-state or process claims

Typical entry friction points for generics

• Attempting to enter with a generic whose manufacturing process does not match a patented controlled process
• Attempting to match brand specs while avoiding infringement of a listed form/polymorph claim
• Design-around via alternative salts or alternative crystal forms

---

What patents protect palonosetron and how does its IP profile differ from ondansetron and granisetron?

Featured snippet answer: Palonosetron’s market positioning often supports stronger remaining commercial differentiation because it is associated with specific clinical and dosing advantages. Its patent estate more commonly supports protection around specific formulations and delivery/clinical regimen-linked claims.

Why palonosetron can sustain differentiation

• Dosing convenience and clinical positioning can keep certain product formats economically relevant.
• Lifecycle protections may remain active longer when they track commercial SKU definitions.

Method-of-use risk

Even when composition-of-matter has expired, remaining risk can shift to:

• Method-of-use claims tied to regimens (CINV and timing)
• Prescription practices that align with labeled use

For ANDA challengers, method-of-use claims matter mainly when labels or proposed use sections can trigger infringement theories.

---

When do 5-HT3 antagonist drugs lose exclusivity and what are the key expiration timelines?

Featured snippet answer: Exclusivity and patent-driven barriers vary by SKU, not by the class. In practice, 5-HT3 antagonist primary molecule protection often lapses well before modern generics enter, shifting timelines to lifecycle patent expirations tied to specific dosage forms.

Practical timeline framework for market entry planning

For each relevant brand SKU, entry timing is governed by:

1. Last granted US patent expiration (including terminal disclaimers where applicable)
2. Listed patents in the Orange Book associated with the exact dosage form/strength
3. Exclusivity (3-year/7-year) if relevant, generally only for newer NDA approvals
4. Litigation-driven stays following Paragraph IV filings

Market reality: class maturity compresses timelines

As more generics secure approvals and market share, remaining “last mile” barriers become:

• A handful of formulation patents that delay or block certain filings
• Settlement agreements that structure launch dates

---

Which companies challenge 5-HT3 antagonists with Paragraph IV ANDAs and how do settlements shape entry?

Featured snippet answer: Paragraph IV challenges in mature 5-HT3 families occur in waves, often led by large generic manufacturers and niche challengers. Settlement agreements commonly set launch timing and define permitted product parameters.

What settlement terms typically do in this class

Settlement agreements for mature small molecules usually:

• Set a specific launch date for the first generic
• Define authorized product characteristics that avoid further dispute (strength, formulation, route)
• Include covenants not to sue for certain claims while reserving rights for later variants

How to model generic entry risk

For each brand SKU, map:

• Which ANDA filers are active
• Which patents are listed for that SKU
• Whether each patent is contested via Paragraph IV or face-value design-around

---

What is the Orange Book status of 5-HT3 receptor antagonist drugs and how many patents are listed per SKU?

Featured snippet answer: Orange Book listings in the 5-HT3 class typically show multiple patents per SKU, but enforceability narrows to a subset of active, unexpired patents that cover the exact route and dosage form.

Orange Book reading strategy for investors and litigators

A practical approach:

• Count patents listed per NDA number + strength + dosage form
• Separate:
  • Composition-of-matter
  • Formulation and method-of-use
  • Manufacturing/process patents
• Identify which patents are:
  • Still within enforceable term
  • Litigated via Paragraph IV
  • Triggered by settlement launch dates

Patent density and what it implies

Higher patent counts often correlate with:

• More lifecycle opportunities
• More design-around space but also more legal complexity

For generic strategists, the relevant subset is the set of patents that are:

• Still active
• Listed for the commercial SKU in question
• Not fully rendered moot by litigation outcomes or expirations

---

How do formulation patents protect injectables, ODTs, and tablet presentations in the 5-HT3 class?

Featured snippet answer: In mature 5-HT3 markets, formulation patents most often protect stability, solid-state form, and dosage-form performance for specific routes such as injection and oral fast-dissolve products.

Injectable formulation patent themes

• Stabilizers and pH/tonicity control strategies
• Impurity and degradation pathway control
• Packaging and storage stability claims (where permitted)

Oral and ODT themes

• Tablet matrix composition
• Disintegrant systems
• Crystalline form control for consistent dissolution and bioavailability
• Manufacturing parameters that preserve solid state

Design-around opportunities for generic entrants

• Use of alternative excipient systems
• Alternative manufacturing process that avoids a claimed parameter
• Selection of a different polymorph or crystalline form where permitted by bioequivalence standards

---

Do method-of-use patents in 5-HT3 antagonists create additional generic entry barriers?

Featured snippet answer: Method-of-use claims can add barriers if they remain active and are tied to labeled regimens that are likely to be used. However, in ANDA practice, the infringement analysis often centers on whether the proposed label induces use covered by claims.

Common method-of-use targets

• Timing windows for administration in CINV protocols
• Multi-day chemotherapy regimen protocols
• Combined use frameworks with other antiemetics

Why label matters more than the drug molecule

For generics:

• If a label is “carved out” (or not induced) from the patented method, infringement risk can be reduced.
• If the method claim aligns with the brand label and the generic proposes the same, litigation risk increases.

---

Which jurisdictions matter most for enforcement of 5-HT3 patent estates?

Featured snippet answer: The US is the dominant arena for entry timing via ANDAs, Orange Book listings, and Paragraph IV litigation. Europe and other jurisdictions matter for enforcement leverage against commercial supply, but US market access is often the gating factor.

US vs. EU enforcement logic

• US: gatekeeping via FDA approval triggers and court decisions on listed patents
• EU: injunction leverage and country-by-country enforcement often changes commercial outcomes for supply chains

---

What generic entry risks exist for 5-HT3 antagonist brands and how do you quantify them?

Featured snippet answer: The most material entry risks come from:

• Whether a specific brand SKU has active formulation or method-of-use patents
• Whether Paragraph IV challenges are already litigated or settled
• Whether a generic can design around without losing bioequivalence or requiring label changes

Quantification framework (actionable)

For each brand SKU:

• Active patent count (unexpired, Orange Book-listed)
• Litigated patents count (Paragraph IV contested)
• Settlement-triggered launch date constraints
• SKU-specific product substitution risk (therapeutic equivalence and prescriber switching)

---

How does the patent landscape for ondansetron compare with granisetron and palonosetron?

Featured snippet answer: Ondansetron is the most crowded and price-pressured due to mature patent status. Granisetron and palonosetron often carry more visible lifecycle and formulation leverage that can delay certain generic SKU entries.

Comparative table: typical IP and competition profile

Active	Typical dominant routes/products	Patent estate profile (US market)	Generic pressure level	Key remaining barriers (often)
Ondansetron	IV/IM, tablets, ODT	Mostly aged; lifecycle-format patents matter by SKU	High	Specific stability/form polymorph, process patents
Granisetron	IV, tablets	More visible lifecycle coverage in certain formats	Medium-high	Solid state, stability, formulation-process claims
Palonosetron	IV, specific regimen positioning	Lifecycle + SKU-linked differentiation; method-of-use risk can persist	Medium	Formulation/specific dosing regimen claims tied to label

---

What patent litigation affects 5-HT3 antagonists right now and what outcomes matter for market entry?

Featured snippet answer: Litigation impacts entry chiefly through:

• court outcomes that uphold listed patents
• or settlement agreements that set launch dates and restrict product characteristics

Litigation outcome mapping for planning

For each active brand SKU:

• Identify which patents were asserted
• Determine whether the case resulted in:
  • dismissal due to invalidity/non-infringement
  • infringement judgments
  • consent judgments and settlement launch dates
• Track whether additional continuations or re-listings alter the enforceability set

---

What commercial outcomes do patent expirations and settlements drive for the class?

Featured snippet answer: Patent expiration in 5-HT3 antagonists usually triggers rapid generic entry for the same dosage forms, with pricing compression and margin shifts. Where formulation or method-of-use patents remain, entry is delayed to specific SKU variants.

What the market tends to do post-expiration

• Generic substitution accelerates for the most prescribed delivery route
• Brands shift toward:
  • remaining SKU protection
  • contracting and payer dynamics
  • patient access programs that reduce net pricing differentials

---

Key Takeaways

• The 5-HT3 antagonist class is mature, with market power anchored by a limited number of actives and differentiated by SKU-specific patents, not by ongoing chemical novelty.
• Remaining patent leverage is concentrated in formulation (solid state, stability, excipients), manufacturing process, and sometimes method-of-use claims tied to labeled regimens.
• US entry timing is primarily governed by Orange Book-listed patents and Paragraph IV litigation or settlement, which often creates structured launch windows.
• Ondansetron faces the highest generic pressure due to older IP status; granisetron and palonosetron tend to show more visible lifecycle barriers by specific product format and route.

---

FAQs

1. Which 5-HT3 antagonist has the highest remaining formulation patent risk for generics?
2. How do Orange Book listings differ across ondansetron vs granisetron by NDA and dosage form?
3. Can a generic avoid infringement in a 5-HT3 method-of-use case by changing the label?
4. What settlement terms most commonly delay generic launches for 5-HT3 antagonists?
5. How does switching from IV to oral formulations change a brand’s patent enforceability and generic entry risk?

---

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). US Food and Drug Administration.
2. FDA. ANDA Paragraph IV Certifications and Patent Listing Requirements. US Food and Drug Administration.
3. US Code. 21 U.S.C. § 355(j) (Hatch-Waxman amendments) and related provisions.
4. FDA. Guidance for Industry: Changes to Approved NDA/ANDA Products; patent and exclusivity implications (as applicable to small molecule lifecycle changes).